Literature DB >> 35138408

Survey of malignant pleural mesothelioma treatment in Japan: Patterns of practice and clinical outcomes in tomotherapy facilities.

Mikiko Nakanishi-Imai1,2, Taro Murai1, Masahiro Onishi3, Atsuto Mouri4, Takafumi Komiyama5, Motoko Omura6, Shigehiro Kudo7, Akihiko Miyamoto8, Masaru Hoshino9, Shinichi Ogawa10, Shizuko Ohashi11, Masahiko Koizumi12, Junichi Omagari13, Hiroshi Mayahara14, Katsuyuki Karasawa15, Toshiyuki Okumura16, Yuta Shibamoto1,17.   

Abstract

We conducted a nationwide survey of tomotherapy for malignant pleural mesothelioma (MPM) in Japan. Fifty-six facilities were surveyed and data on 31 patients treated curatively between 2008 and 2017 were collected from 14 facilities. Twenty patients received hemithorax irradiation after extrapleural pneumonectomy (EPP) (first group). Five patients received irradiation without EPP (second group), while six received salvage radiotherapy for local recurrence (salvage group). Among the seven patients not undergoing EPP, five (four in the second group and one in the salvage group) were treated with lung sparing pleural irradiation (LSPI) and two with irradiation to visible tumors. Two-year overall survival (OS) rates in the first and second groups were 33% and 60%, respectively (median, 13 vs 30 months, P = 0.82). In the first and second groups, 2-year local control (LC) rates were 53 and 67%, respectively (P = 0.54) and 2-year progression-free survival (PFS) rates were 16% and 60%, respectively (P = 0.07). Distant metastases occurred in 15 patients in the first group and three in the second group. In the salvage group, the median OS was 18 months. Recurrence was observed in the irradiated volume in four patients. The contralateral lung dose was higher in LSPI than in hemithorax irradiation plans (mean, 11.0 ± 2.2 vs 6.1 ± 3.1 Gy, P = 0.002). Grade 3 or 5 lung toxicity was observed in two patients receiving EPP and hemithorax irradiation, but not in those undergoing LSPI. In conclusion, outcomes of EPP and hemithorax irradiation were not satisfactory, whereas LSPI appeared promising and encouraging.
© The Author(s) 2022. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Entities:  

Keywords:  hyperthermia; intensity-modulated radiotherapy (IMRT); lung sparing pleural irradiation (LSPI); malignant pleural mesothelioma (MPM); nationwide survey in Japan; tomotherapy; whole hemithorax irradiation (WHI)

Mesh:

Year:  2022        PMID: 35138408      PMCID: PMC8944311          DOI: 10.1093/jrr/rrab127

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  26 in total

Review 1.  A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Christopher Q Cao; Tristan D Yan; Paul G Bannon; Brian C McCaughan
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

2.  Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.

Authors:  Emilio Minatel; Marco Trovo; Alessandra Bearz; Matteo Di Maso; Tania Baresic; Annalisa Drigo; Loredana Barresi; Carlo Furlan; Alessandro Del Conte; Gioia Bruschi; Paolo Fontana; Vittore Pagan; Giovanni Franchin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-06-20       Impact factor: 7.038

3.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

4.  Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Claus Andrup Kristensen; Trine Juhler Nøttrup; Anne Kiil Berthelsen; Flemming Kjaer-Kristoffersen; Jesper Ravn; Jens Benn Sørensen; Svend-Aage Engelholm
Journal:  Radiother Oncol       Date:  2009-04-11       Impact factor: 6.280

5.  Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.

Authors:  Andreas Rimner; Daniel E Spratt; Marjorie G Zauderer; Kenneth E Rosenzweig; Abraham J Wu; Amanda Foster; Ellen D Yorke; Prasad Adusumilli; Valerie W Rusch; Lee M Krug
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-26       Impact factor: 7.038

6.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

7.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Authors:  Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto
Journal:  Lancet Oncol       Date:  2011-06-30       Impact factor: 41.316

8.  Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Occup Environ Med       Date:  2020-03       Impact factor: 4.402

9.  British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.

Authors:  Ian Woolhouse; Lesley Bishop; Liz Darlison; Duneesha De Fonseka; Anthony Edey; John Edwards; Corinne Faivre-Finn; Dean A Fennell; Steve Holmes; Keith M Kerr; Apostolos Nakas; Tim Peel; Najib M Rahman; Mark Slade; Jeremy Steele; Selina Tsim; Nick A Maskell
Journal:  Thorax       Date:  2018-03       Impact factor: 9.139

10.  Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial.

Authors:  Robert C Rintoul; Andrew J Ritchie; John G Edwards; David A Waller; Aman S Coonar; Maxine Bennett; Eleonora Lovato; Victoria Hughes; Julia A Fox-Rushby; Linda D Sharples
Journal:  Lancet       Date:  2014-06-16       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.